* absolute contraindication of lenalidomide use or hypersensitivity to the active ingredient or any of the excipients. * active neoplasia * previous autoimmune disease * concurrent infection of hbv, hcv or tuberculosis. * aspartate transaminase (ast) or alanine transaminase (alt) \> 3 times the upper limit of normal (uln). * bilirubin levels \> 1.5 times the uln * renal impairment with an estimated gf \< 30ml/min * venous thromboembolism events within the previous 3 years * significant active heart disease within the previous 6 months, including congestive heart failure (class ii-iv nyha), unstable angina or myocardial infarctions * sexually active subjects who refuse the lenalidomide risk minimization program * inability to comply with the working protocol under the responsible health professional opinion.

* absolute contraindication of lenalidomide use or hypersensitivity to the active ingredient or any of the excipients. * active neoplasia * previous autoimmune disease * concurrent infection of hbv, hcv or tuberculosis. * aspartate transaminase (ast) or alanine transaminase (alt) \> 3 times the upper limit of normal (uln). * bilirubin levels \> 1.5 times the uln * renal impairment with an estimated gf \< 30ml/min * venous thromboembolism events within the previous 3 years * significant active heart disease within the previous 6 months, including congestive heart failure (class ii-iv nyha), unstable angina or myocardial infarctions * sexually active subjects who refuse the lenalidomide risk minimization program * inability to comply with the working protocol under the responsible health professional opinion.

- absolute contraindication of lenalidomide use or hypersensitivity to the active ingredient or any of the excipients. - active neoplasia - previous autoimmune disease - concurrent infection of hbv, hcv or tuberculosis. - aspartate transaminase (ast) or alanine transaminase (alt) > 3 times the upper limit of normal (uln). - bilirubin levels > 1.5 times the uln - renal impairment with an estimated gf < 30ml/min - venous thromboembolism events within the previous 3 years - significant active heart disease within the previous 6 months, including congestive heart failure (class ii-iv nyha), unstable angina or myocardial infarctions - sexually active subjects who refuse the lenalidomide risk minimization program - inability to comply with the working protocol under the responsible health professional opinion.

- absolute contraindication of lenalidomide use or hypersensitivity to the active ingredient or any of the excipients. - active neoplasia - previous autoimmune disease - concurrent infection of hbv, hcv or tuberculosis. - aspartate transaminase (ast) or alanine transaminase (alt) > 3 times the upper limit of normal (uln). - bilirubin levels > 1.5 times the uln - renal impairment with an estimated gf < 30ml/min - venous thromboembolism events within the previous 3 years - significant active heart disease within the previous 6 months, including congestive heart failure (class ii-iv nyha), unstable angina or myocardial infarctions - sexually active subjects who refuse the lenalidomide risk minimization program - inability to comply with the working protocol under the responsible health professional opinion.